Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in New Delhi, India
Authors:
- Dinesh Chandra DovalDDDinesh Chandra Doval
- Anila SharmaASAnila Sharma
- Rupal SinhaRSRupal Sinha
- Kapil KumarKKKapil Kumar
- Ajay Kumar DewanADAjay Kumar Dewan
- Harit ChaturvediHCHarit Chaturvedi
- Ullas BatraUBUllas Batra
- Vineet TalwarVTVineet Talwar
- Sunil Kumar GuptaSGSunil Kumar Gupta
- Shailendra SinghSSShailendra Singh
- Vidula BholeVBVidula Bhole
- Anurag MehtaAMAnurag Mehta
Open Access
- 13 July 2015
- journal article
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 16 (12) , 4959-4964
Abstract
To assess the immunohistochemical expression of estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor-2 (HER2) neu receptor in breast cancer and their associations with various clinicopathological characteristics. This is a retrospective analysis of women who presented with primary, unilateral breast cancer in the Department of Medical Oncology at Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India during the period from January 2008 to December 2011. Data were retrieved from the medical records of the hospital including both early and locally advanced cancer cases. ER, PgR and HER2neu expression in these patients was assessed and triple negative patients were identified. Associations of triple negative and non-triple negative groups with clinicopathological characteristics were also evaluated. A total of 1,284 women (mean age 52.1 years, 41.9% premenopausal) were included in the analysis. Hormone receptor positivity (ER and/or PgR) was seen in 63.4% patients, while 23.8% of tumors were triple negative. Only 23.0% were HER2 positive. Around 10.0% of tumors were both ER and HER2 positive. ER and PgR positivity was significantly associated with negative HER2 status (p-value<0.0001). Younger age, premenopausal status, higher tumor grade, lymph node negativity, advanced cancer stage, and type of tumor were strongly associated with triple negativity. Significantly, a smaller proportion of women had ductal carcinoma in situ in the triple negative group compared with the non-triple negative group (35.6% versus 60.8%, p-value<0.01). The present analysis is one of the largest studies from India. The majority of the Indian breast cancer patients seen in our hospital present with ER and PgR positive tumors. The triple negative patients tended to be younger, premenopausal, and were associated with higher tumor grades, negative lymph nodes status and lower frequency of ductal carcinoma in situ.Keywords
This publication has 13 references indexed in Scilit:
- Epidemiological Correlates of Breast Cancer in South IndiaAsian Pacific Journal of Cancer Prevention, 2013
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31Journal of Clinical Oncology, 2011
- Estrogen Receptor Negative Breast Cancer in India: Do We Really Have Higher Burden of this Subtype?Indian Journal of Surgical Oncology, 2011
- Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologistsLaboratory Investigation, 2011
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Hormone receptors over the last 8 years in a cancer referral center in India: What was and what is?Indian Journal of Pathology and Microbiology, 2009
- Comparison of triple‐negative and estrogen receptor‐positive/progesterone receptor‐positive/HER2‐negative breast carcinoma using quantitative fluorine‐18 fluorodeoxyglucose/positron emission tomography imaging parametersCancer, 2007
- Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 statusAnnals of Oncology, 2006
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998